Open AccessEarly effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers
Author(s) -
Hatsushi Yamagishi,
Tomoyuki Koike,
Shuichi Ohara,
Toru Horii,
Ryousuke Kikuchi,
Shigeyuki Kobayashi,
Yasuhiko Abe,
Katsunori Iijima,
Akira Imatani,
Kaori Suzuki,
Takanori Hishinuma,
Junichi Goto,
Tooru Shimosegawa
Publication year - 2008
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.14.2049
Subject(s) - lansoprazole , rabeprazole , cyp2c19 , pharmacology , omeprazole , medicine , gastric acid , drug , oral administration , chemistry , gastroenterology , stomach , cytochrome p450 , metabolism
To compare rabeprazole (RPZ; 10 mg) with Lansoprazole orally disintegrating tablets (LPZ; 30 mg OD) in terms of antisecretory activity and blood drug concentration after a single dose.